NEULANDLAB · NSE
Neuland Laboratories Limited
₹20,642
-2.18% (-₹460)
Prev. close
₹21,102
Volume
37,328
Delivery %
51.2%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “JM Financial holds the highest price target for Neuland Laboratories at ₹25,819, implying a significant upside potential…” | JM Financial AnalysisJM Financial Institutional Securities | Neuland Laboratories | PENDING | |
| “Bullish on Neuland Laboratories, recommending a buy at ₹14247.65 with a target of ₹15000 and a stop loss at ₹13700 for i…” | Sumeet BagadiaChoice Equity Broking | Neuland Laboratories Ltd | PENDING |
Long-Horizon calls · 1yr+ horizon · verdict pending
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Neuland Labs with a price target of ₹19,700 per share. Expects the total addressable market to grow at 15% CA…” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Neuland Laboratories Ltd | HIT |
Fundamentals
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Davuluri Saharsh Rao
Headquarters
Hyderabad
Employees
2,183
Website
neulandlabs.comExchange
View on NSE ↗Key stats
Market cap
₹25,115.79 Cr
P/E ratio (TTM)
55.5
Dividend yield
0.18%
EPS (TTM)
₹352.72
Beta (1Y · daily vs NIFTY 50)
0.85
Beta (5Y · monthly vs NIFTY 50)
1.36
Shares float
73.55 L
EPS · quarter ended Jun 2026
₹115.10
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹936.91 Cr | ₹951.08 Cr | ₹1,191.20 Cr | ₹1,558.58 Cr | ₹1,476.84 Cr | ₹2,022.99 Cr | |
EBITDA | ₹162.91 Cr | ₹144.70 Cr | ₹281.59 Cr | ₹475.13 Cr | ₹420.17 Cr | ₹604.66 Cr |
| ₹80.63 Cr | ₹63.82 Cr | ₹163.52 Cr | ₹300.08 Cr | ₹260.11 Cr | ₹364.00 Cr | |
Diluted EPS | ₹62.85 | ₹49.74 | ₹127.45 | ₹233.89 | ₹202.74 | ₹283.71 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹1,383.49 Cr | ₹1,579.76 Cr | ₹1,832.56 Cr | ₹2,179.88 Cr | ₹2,930.14 Cr | |
| — | ₹240.53 Cr | ₹128.45 Cr | ₹95.39 Cr | ₹157.14 Cr | ₹301.27 Cr | |
Stockholders' equity | — | ₹840.50 Cr | ₹994.10 Cr | ₹1,282.70 Cr | ₹1,524.81 Cr | ₹1,874.47 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹189.36 Cr | ₹58.58 Cr | ₹237.21 Cr | ₹261.18 Cr | ₹317.38 Cr | ₹346.68 Cr | |
Investing cash flow | ₹-84.42 Cr | ₹-93.71 Cr | ₹-61.50 Cr | ₹-149.69 Cr | ₹-298.16 Cr | ₹-423.73 Cr |
| ₹-113.66 Cr | ₹37.72 Cr | ₹-135.80 Cr | ₹-69.28 Cr | ₹24.96 Cr | ₹20.98 Cr | |
Capital expenditure | ₹-105.40 Cr | ₹-96.89 Cr | ₹-66.13 Cr | ₹-143.67 Cr | ₹-206.46 Cr | ₹-397.13 Cr |
End cash position | — | ₹5.09 Cr | ₹45.42 Cr | ₹87.58 Cr | ₹131.93 Cr | ₹76.67 Cr |
Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Sep 22(5Q) | Dec 22–Mar 23(2Q) | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24–Jun 25(3Q) | Sep 25 | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 36.22% | 36.14% | 36.03% | 35.97% | 32.80% | 32.74% | 32.72% | 32.64% | 32.68% | 32.64% | 32.63% | 32.62% |
| Public | 63.78% | 63.86% | 63.97% | 64.03% | 67.20% | 67.26% | 67.28% | 67.36% | 67.32% | 67.36% | 67.37% | 67.38% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Neuland Laboratories Limited | ₹24,920.78 Cr | ₹19,576 | 50.1 | 13.29 | 19.4% | 0.16 | +34.7% | +11.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Neuland Laboratories falls 2.85% in Friday's session
Global Banking & Finance Review · 2 days ago
Neuland Laboratories September profit falls 47% on sales decline
Multibagg AI · 18 days ago